Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet a…
An institutional-grade, numbers-driven thesis on REGN — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Regeneron Pharmaceuticals, Inc. (REGN) 69/100 with a 12-month base-case forecast of $819.59 — +4.5% versus the current price of $784.36. Regeneron Pharmaceuticals, Inc. trades at $784.36 in the Healthcare sector, with a market capitalisation of $80.81B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for REGN is $819.59, implying +4.5% versus the current price. The model's 12-month scenario range runs from $905.45 (bear) to $1057.69 (bull), with a base case of $941.80.
On the fundamentals, Regeneron Pharmaceuticals shows a P/E of 18.7, trailing revenue of $14.34B, revenue growth of +1.0% YoY, a dividend yield of 0.46%. This page also tracks REGN's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
REGN currently carries a TradersQuant composite score of 69/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $819.59 implies +4.5% from $784.36. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for REGN is $819.59, about +4.5% versus the latest price of $784.36. Consensus is based on 49 analysts.
TradersQuant's 12-month model forecast for REGN is a base case of $941.80, ranging from $905.45 (bear) to $1057.69 (bull), an expected return of +20.1%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for REGN over the next 12 months is $941.80 in the base case (bear $905.45, bull $1057.69), versus today's price of $784.36. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for REGN — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates REGN's fair value at $819.59, implying +4.5% of expected upside versus the current price.
Yes — Regeneron Pharmaceuticals pays a dividend yielding 0.46% (about $3.64 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
